Stay updated with breaking news from 0fgen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FibroGen, Inc. (NASDAQ:FGEN – Get Free Report) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totalling 7,870,000 shares, an increase of 18.9% from the June 15th total of 6,620,000 shares. Approximately 8.8% of the shares of the stock are sold short. Based on […]
Raymond James downgraded shares of FibroGen (NASDAQ:FGEN – Free Report) from an outperform rating to a market perform rating in a research note published on Monday morning, The Fly reports. FGEN has been the subject of several other reports. William Blair cut FibroGen from an outperform rating to a market perform rating in a research […]
By Chris Wack FibroGen shares were down 84% at $2.75, a new 52-week low, after the company said that its Phase 3 trial of pamrevlumab in patients with...
FibroGen (NASDAQ:FGEN – Get Rating) was downgraded by investment analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research report issued on Monday, The Fly reports. FGEN has been the topic of a number of other research reports. Bank of America cut shares of FibroGen from a “buy” rating to […]
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) insider Thane Wettig sold 791 shares of FibroGen stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $16.53, for a total value of $13,075.23. Following the completion of the transaction, the insider now owns 108,261 shares of the company’s stock, valued […]